compound
Navigation Links
compound at medicine technology
Appendicitis: Evolving Tools to Diagnose a Classic Disease
...ose over 50, rises as appendectomy is delayed. To compound the problem, numerous diseases mimic appendicitis, and it is often difficult to rule it out based on clinical presentation. This is due to well-known variance in history and physical exam. For example, the classic symptoms of abdominal pain, nausea...Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
...n 2008 and to explore thepotential benefits of the compound in various other solidtumours. Glyn Edwards, Antisoma's CEO said, "Our ovarian cancer trial hasnot produced positive results like those seen with ASA404 in lungcancer. More broadly, we're very pleased with the progress made byNovartis to date with A...Sygnis Pharma AG announces date for presentation of clinical results
...al phase IIa study forAX200 (AXIS-study). AX200, a compound for the treatment of stroke, is the mostadvanced drug candidate in SYGNIS’ product pipeline. Theprimary aim of the study is to show safety and tolerability ofAX200 in acute stroke patients. The results of the AXIS-study areexpected to provide i...Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
...hisfield is highlighted by the following: * Lead compound MC-1 in pivotal Phase 3 study for FDA approval *Four positive Phase 2 trials completed with MC-1 * FDA Fast Trackdesignation for MC-1 * U.S. rights to AGGRASTATR Injection(tirofiban hydrochloride) * Combination of MC-1 and lisinopril(MC-4232) complet......ained about strong pain. The 10% dose of theactive compound ALA was superior to the other doses tested.Consequently, Biofrontera will conduct additional studies to verifythe safety and efficacy of this concentration in preparation forits registration. "This result impressively demonstrates the great potentia......of oral anticoagulants, and Portola has apromising compound with compelling drug characteristics resultingin consistent activity without the need for dose adjustment ormonitoring. We will be closely following PRT054021 as it progressesinto late-stage clinical trials." Dr. Turpie discussed these data today in...... is designedto evaluate this clinical finding. The compound is not currentlyapproved in the United States. The most common adverse events reported in ACTEMRA globalclinical studies are upper respiratory tract infections, headache,nasopharyngitis and hypertension. As with other biological diseasemodifying ant......n skipping technology. AVI's lead NEUGENEantisense compound is designed to target cell proliferationdisorders, including cardiovascular restenosis. In addition totargeting specific genes in the body, AVI's antiviral program usesNEUGENE antisense compounds to combat disease by targetingsingle-stranded RNA viru......ide valuable information aboutthis investigational compound and its potential in patients withadvanced breast cancer that is no longer responding to any of thecurrent U.S. approved chemotherapy treatments." The 126 patients enrolled in the single-arm Phase II study(CA163081) had heavily pretreated, advanced ...... which outlines Phase II data on the Company'slead compound PRT054021, is entitled "Evaluation of the Factor X...in clinical development.Portola believes that this compound may provide significantclinical benefit through immediate, high-level platelet inhibitionin the acut...Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
... in vitro experiments that an investigational drug compound knownas CSA-13 shows promise as a potential therap...uggestingpotential for therapeutic use. "This new compound has the potential to be a significant advancein the treatment of patients with cystic fibrosis and o......ed to as KRX-101, a first-in-class, oralheparinoid compound for the treatment of diabetic nephropathy, alife-t...eloping Zerenex(TM), an oral, inorganic,iron-based compound that has the capacity to bind phosphate andform non-absorbable complexes. Zerenex is currently in Ph...Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
...arathyroidism." About CTA018 CTA018 is the first compound in a new class of active Vitamin Danalogs having a... but safer than currentlyavailable therapies. This compound was specifically designed byProfessor Gary H. Posner, Ph.D. and is protected under patents andpatent...Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
...c patients withmild-to-moderate hypertension. This compound is the first of a nextgeneration of renin inhibito... the CHMP in Europe[2]. SPP635 is themost advanced compound in the SPP600 series and is one of severalnew proprietary renin inhibitors invented by Speedel Exper...Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target
... program. • Corifollitropin alfa is the first compound in a new class oflong-acting fertility hormones called ‘Sustained FollicleStimulants’ (SFS). The primary advantage of an SFS overcurrent gonadotropins is the longer duration of action which allowsa treatment regimen replacing 7 daily inje......ditionally, the company has indevelopment AV513, a compound for the treatment of hemophilia A andB. For more information about Avigen, consult the company's websiteat <a target="_blank" href="http://www.avigen.com/">http://www.avigen.com . The Avigen, Inc. logo is available at <a target="_blank" ......ty profile of multiple doses of theinvestigational compound dapagliflozin, a selective inhibitor ofthe Sodium-...eing studied as a once-daily oral antidiabetic.The compound has a novel proposed mechanism of action, selectivelyinhibiting sodium glucose cotransporter 2 (SGLT......ileadhiv.com/">www.GileadHIV.com . The parent compound of Viread was discovered through acollaborative re...studies may notwarrant further development of this compound for the treatment ofchronic hepatitis B and completing our clinical studies may takelonger or cost m...Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
...ment ofDG041, the company's Phase II developmental compound for theprevention of arterial thrombosis. The results of the Phase IIa andclinical pharmacology studies presented today build upon previousfindings demonstrating DG041's profile as an anti-platelet compoundthat deCODE expects will make it possible to...... Hematide is a novel synthetic, pegylated peptidic compound thatbinds to and activates the erythropoietin receptor. The product isbeing developed for treatment of anemia in patients with chronicrenal failure and cancer patients receiving chemotherapy. About Affymax, Inc. Affymax, Inc. is a biopharmaceutical......ion is available at www.GileadHIV.com. The parent compound of Viread was discovered through acollaborative re...studies may notwarrant further development of this compound for the treatment ofchronic hepatitis B and completing our clinical studies may takelonger or cost m......omposition ofmatter protection covering five novel compound classes and theirtherapeutic uses. About Elixir Pharmaceuticals Elixir is a Cambridge, MA-based biopharmaceutical companyfocused on developing and commercializing drugs to treat andprevent metabolic disease, prevent age-related diseases, ultimately......gressively damaged. Sulonex is a glycosaminoglycan compound withstructural similarities to the broad family of...ed to as KRX-101, a first-in-class, oralheparinoid compound for the treatment of diabetic nephropathy, alife-threatening kidney disease caused by diabetes. Sulo......rgeted Tumor Therapy with the TGF-beta 2 antisense compound AP12009, Cytokine Growth Factor Reviews 17 (2006): 129-139 Disclaimer This document contains forward-looking statementswith respect to the future business of Antisense Pharma GmbH. Bytheir nature, forward-looking statements and forecasts involverisk...Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
...rring hormone Glucagon-Like Peptide-1 (GLP-1). The compound isbeing developed by Novo Nordisk for the treatment of type 2diabetes, and is currently in phase 3 development. Liraglutideworks by stimulating the release of insulin only when glucoselevels become too high. In contrast to most other antidiabetictrea...Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
...f AVN944 have beeninitiated in 46 patients and the compound is well tolerated.Pharmacokinetics measurements indicate dose proportional plasmalevels of AVN944 during treatment and sustained plasmaconcentrations at the dose levels tested thus far. Early Activity Indicators: This Phase I study is designed toeva......ase and potentactivity in HCV replicon assays. The compound also displayed verygood in vitro metabolic stability and did not significantly inhibithuman CYP enzymes, suggesting a low potential for drug-druginteractions. Extending these in vitro findings, in vivopreclinical studies of ANA598 demonstrated high o...... protocol to evaluate the safety and impactof this compound on specific metabolic processes altered by chronic...s results and are lookingforward to subjecting the compound to more rigorous tests tosupport eventual commercialization." About The Study The study results de...Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
...he outermitochondrial membrane suggesting that the compound has potentialin a range of additional commercially... neurondisease employed to support the use of this compound to treat ALS,as well as spinal muscular atrophy. TRO19622 is currently in aPhase IIa clinical trial ......with cancer andother serious diseases. Its initial compound AVR118 represents anew class of cytoprotective agent that targets among other things,cachexia related disorders. AVR118 has also shown to have topicalwound healing properties in animal models. Various degenerativeconditions associated with body wasti......cer ScreeningApoptosis Program, through which this compound was discovered." The Cancer Research authors de...ion due to vascular disruption activity (VDA). The compound iscurrently being evaluated in two Phase II human clinical trials,one in patients with primary brain...New Positive Pre-clinical Data for Active Biotech's RA Project I-3D
...acute;asson President and CEO About I-3D The I-3D compound is a novel small molecule inhibitorof human dihydroorotate dehydrogenase (DHODH). Inflammatorydiseases such as RA involve rapidly proliferating T cells with anexceptional requirement for de novo pyrimidine biosynthesis. DHODHinhibition results in inh......luding several European countries and the USA. The compound isnot currently approved in the United States. The most common adverse events reported in ACTEMRA(TM) globalclinical studies are upper respiratory tract infections, headache,nasopharyngitis and hypertension. As with other biological diseasemodifying......tofollow-up with Merck in their advancement of the compound towardsdevelopment in HIV/AIDS patients. - On April 24th, Ambrilia announced the positive findings of aU.S. Phase I/II study which showed that its therapeutic peptidedrug PCK3145 had clinical activity in late-stage prostate cancerpatients. PCK3145 w...Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
...phandrugs." About Liarozole Liarozole is a novel compound that belongs to a new class ofdrugs known as retinoic acid metabolism blocking agents, or RAMBAs.Retinoic acid, also known as vitamin A, is essential for optimalfunctioning of the skin. In contrast to current synthetic retinoidtreatments, which intro...Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo
....Vanda's lead product candidate, iloperidone, is a compound for thetreatment of schizophrenia and has complete...am.Vanda's second product candidate, VEC-162, is a compound for thetreatment of sleep and mood disorders which is currently in PhaseIII for insomnia. Vanda's th...... 2a clinical studies for NG2-73, the Company'slead compound for the treatment of insomnia, were presented in twosessions at the SLEEP 2007 Annual Meeting of the AssociatedProfessional Sleep Societies (APSS) in Minneapolis, Minnesota. TwoPhase 2b clinical studies with NG2-73 in chronic insomnia patientsare cur...... In both studies the safety and tolerabilityof the compound were confirmed by the absence of serious adverseevents, clinically significant laboratory findings, oxygensaturation level alterations, and electrocardiogram (ECG)abnormalities. In these studies, NG2-73 was shown to be a novel sedativehypnotic which......y neuroprotective mechanism of thisfirst-in- class compound is also being evaluated in clinical trialsfor Age-Associated Memory Impairment and Parkinson's disease. About Accera, Inc. Based in Broomfield, CO, Accera, Inc. is a privately heldbiotechnology company focused on developing novel drugs forneurodege...Inspire Announces Presentations at Two European Scientific Conferences
...wo presentations with clinical dataon bilastine, a compound in development by FAES Farma, S.A. for thetreatmen...wo presentations with clinicaldata on denufosol, a compound in development by Inspire for thetreatment of cystic fibrosis. -0- -- Deposition and Pharmacokineti...... by GlaxoSmithKline. PROMACTAis an investigational compound that has not received regulatoryapproval in any market for any indication at this time. Ongoing Trials Several PROMACTA trials investigating the short- and long-termtreatment of chronic ITP are currently open and enrolling.(5)EXTEND (Eltrombopag eX...Karo Bio Announces Sucessfule Phase II Results of KB2115
...B2115 induces a significantlowering of LDL and the compound appears to be safe in a longerstudy. We strongly b...n thefuture treatment of dyslipidemia and that the compound may well bea candidate for use in a broader patient population". KARO BIO AB For further informati...Clinical Update - Debio 9902 (ZT-1) for Alzheimer's Disease
... having the potential of being aneuroprotectant. A compound with neuroprotective properties tocomplement the cholinergic effect, could potentially reduce theprogression of AD. Debiopharm is seeking a partner for furtherdevelopment and commercialisation of Debio 9902. About Debiopharm Group Debiopharm Group ...Promising Data on Cognitive Effects of Safinamide in Early Parkinson's Disease
...k Serono S.A., which has the rights to develop the compound inPD, Alzheimer´s disease, other cognitive disorders andRestless Legs Syndrome. Recent results of a six-month phase IIItrial of safinamide in PD demonstrated its benefit in motorsymptoms and activities of daily living, as well as its improvemen.......Vanda's lead product candidate, iloperidone, is a compound for thetreatment of schizophrenia and bipolar diso...ia. Vanda's secondproduct candidate, VEC-162, is a compound for the treatment ofsleep and mood disorders which is currently in Phase III forinsomnia. Vanda's th...Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study
...ipation,we’ve unlocked the potential of this compound as a treatmentfor two distinct and underserved GI ...o well-tolerated. Previousclinical studies of the compound have demonstrated favorable safetyand pharmacokinetic profiles. Dynogen has exclusive rightsunder i......ion is available at www.GileadHIV.com. The parent compound of Viread was discovered through acollaborative re...studies may not warrant furtherdevelopment of this compound for the treatment of chronic hepatitisB and completing our clinical studies may take longer or cost ...Dynogen Reports Positive Results in Phase 1B GERD Study
... constipation, we'veunlocked the potential of this compound as a treatment for twodistinct and underserved GI ...so well-tolerated.Previous clinical studies of the compound have demonstratedfavorable safety and pharmacokinetic profiles. Dynogen hasexclusive rights under is...XTL Provides Update on Phase I Clinical Trial of XTL-2125
...e, clinical andbusiness prospects for our clinical compound for neuropathic pain,Bicifadine, and for our pre-clinical compounds for hepatitis C fromour XTL-DOS program, growth and operating strategies and similarmatters, may be forward-looking statements that involve a number ofrisks and uncertainties. For th......or fluctuations asmeasured by patient diaries. The compound had positive effects inthree critical areas: "core...nfirmed in the Phase IIb and subsequenttrials, the compound would address a very important unmet medicalneed for all mid-to-late stage patients developing postu......(oblimersen sodium) Injection is theCompany's lead compound from its oligonucleotide program. Theleading drug in Genta's small molecule program is Ganite(R)(gallium nitrate injection), which the Company is exclusivelymarketing in the U.S. for treatment of symptomatic patients withcancer related hypercalcemia ...Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
...Beutner, Anacor's chiefmedical officer. "A topical compound that effectively targetsTNF-alpha would have great promise, and we intend to initiatefurther clinical trials to characterize the clinical utility ofthis drug in psoriasis and other inflammatory skin diseases." Psoriatic plaques on each of the 12 p......omposition ofmatter protection covering five novel compound classes and theirtherapeutic uses. About Elixir Pharmaceuticals Elixir is a Cambridge, MA-based biopharmaceutical companyfocused on developing and commercializing drugs to treat andprevent metabolic disease, prevent age-related diseases, ultimately...Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
...egulatoryapproval and/or market acceptance for any compound or new productincluding MGCD0103, MGCD265 or MGCD2...cal trialprogram for XL880, a novel small molecule compound thatsimultaneously inhibits MET and VEGFR2, targets implicated in tumorgrowth, tumor cell migration,......trolling cancer.MAGE-A3 ASCI is an investigational compound and it is not approvedfor use in any indication in any country at this time. About Non-Small Cell Lung Cancer According to the World Health Organization (WHO), more than 1.3million new cases of lung and bronchus cancer are diagnosed eachyear worldw......oblimersen sodium) Injection is the Company's lead compound from its oligonucleotideprogram. The leading drug in Genta’s small molecule program is Ganite® (galliumnitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomaticpatients with cancer related hyper...Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program
...in a Phase IIstudy. "DTS-201 is a safe and active compound which allowed delivery ofa high dose of doxorubicin without any unexpected side effects,"stated Jean-Pierre Delord, M.D., principal investigator from theanti-cancer center Claudius Regaud Institute in Toulouse, France."In particular, no severe toxici......(oblimersen sodium) Injection is theCompany's lead compound from its oligonucleotide program. Theleading drug in Genta's small molecule program is Ganite(R)(gallium nitrate injection), which the Company is exclusivelymarketing in the U.S. for treatment of symptomatic patients withcancer related hypercalcemia ...... and manageable side effectprofile. This promising compound warrants continueddevelopment." "KOS-1584/R1645 is a highly potent compound with attractivepharmaceutical properties, including a long half-life, large volumeof distribution, w......umorblood flow, but can also be metabolized into a compound which couldassist with killing the remaining tumor cells at the periphery ofthe tumor by direct cytotoxic activity against tumor cells. InDecember 2004, the United Kingdom regulatory authorities acceptedan application from our collaborators, Cancer R...Other ContentsaldosteronealdosteroneallergenallergenallergenalkaptonuriaallergicallergicallergicallergicallergicallergicallergicallergicaloealoeareataalopeciaalopeciaalopeciaOther TagssliceSADableableableableableableabledecayineffectivechargechargesoresoreOther Tagslessen 2lessen 3lessen 4lessen 5lessen 6surprise 2surprise 3surprise 4surprise 5surprise 6surprise 7loves 2too 2too 3too 4too 5too 6too 7too 8too 9too 10exercise 2exercise 3exercise 4exercise 5exercise 6exercise 7exercise 8exercise 9exercise 10navigate 2healthier 2gone 2gone 3gone 4
(Date:8/28/2008)... Troy, N.Y. The advantage of using two eyes to s...lely with our capacity to see in 3-D. Now, a new s...stitute has uncovered a truly eye-opening advantag...things. , Most animals fish, insects, reptiles,... non-cluttered environments like fields or plains,...
(Date:8/28/2008)...searchers at The University of Nottingham have bee...elop a new drug that could ease the suffering of h... are unable to take beta-blockers. , In the UK, ...ost are able to have their symptoms effectively ma...which stop adrenaline from making the heart work t...
(Date:8/27/2008)..., DALLAS Aug. 28, 2008 Researchers at UT South...t the brain must create new nerve cells for either...like behavior. , In addition, the researchers fo... biochemical pathway to exert their effects. , T...nisms of antidepressants and provide a new directi...
(Date:8/27/2008)...DIANAPOLIS Indiana University researchers have in...omplex problems of scientific collaboration. , D...rative social networking for the science community...nage research papers and data, organize groups and...customize personal and group profiles all online....
Breaking Biology News(10 mins):Study says eyes evolved for X-Ray vision 2Study says eyes evolved for X-Ray vision 3New beta-blocker to offer hope to heart and lung sufferers 2Antidepressants need new nerve cells to be effective, UT Southwestern researchers find 2Indiana U researchers launch social networking and research management tool for scientists 2Study Finds Fever may Lead to Improved Behavior in Children with Autism Spectrum Disorders 960 1Study Finds Fever may Lead to Improved Behavior in Children with Autism Spectrum Disorders 960 2Study Finds Fever may Lead to Improved Behavior in Children with Autism Spectrum Disorders 960 3Study Finds Fever may Lead to Improved Behavior in Children with Autism Spectrum Disorders 960 4Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds 957 1Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds 957 2Red alert 3A Wild strawberries may reduce cancer risk 7399 1Red alert 3A Wild strawberries may reduce cancer risk 7399 2Young chimps top adult humans in numerical memory 1422 1Young chimps top adult humans in numerical memory 1422 2(Date:8/27/2008)... The American Society for Therapeutic Radiology an...ist Audrey Evans, M.D., as its 2008 honorary membe...Ceremony held Tuesday, September 23, at 10:00 a.m....r. Evans has been on the forefront of the treatmen...as one of the co-founders of the original Ronald M...
(Date:8/27/2008)...inding could lead to new drugs in fight against ob... (HealthDay News) -- A chemical produced in the br... likelihood of becoming obese, according to a new ...a group of 33 people who had WAGR syndrome, a gene...illion people. WAGR is an acronym for the symptoms...
(Date:8/27/2008)...dding Velcade to standard drug therapy prolonged s... 27 (HealthDay News) -- Patients with multiple mye... lived longer and better by adding the drug Velcad...he finding could make multiple myeloma, a cancer o...a lethal disease. And it would be particularly val...
(Date:8/27/2008)...tudy also uncovers risks associated with treating ...DAY, Aug. 27 (HealthDay News) -- Scientists from t...st gene directly associated with the onset of seve... age-related macular degeneration that currently t...ericans. , The discovery, based on work with bo...
Breaking Medicine News(10 mins):Health News:ASTRO selects pediatric oncologist as 2008 honorary member 2Health News:Low Levels of Brain Chemical May Control Appetite 2Health News:Combination Therapy Helps to Combat Myeloma 2Health News:Combination Therapy Helps to Combat Myeloma 3Health News:Gene Linked to 'Dry' Macular Degeneration 2Health News:Gene Linked to 'Dry' Macular Degeneration 3| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |